Ivosidenib + Azacitidine Ups Event-Free Survival in IDH1-Mutated AML

THURSDAY, April 21, 2022 -- Compared with placebo and azacitidine, the combination of ivosidenib and azacitidine prolongs event-free survival for patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are ineligible for induction...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news